Effectiveness and Feasibility of Transvaginal Ultrasound–Guided Platelet-Rich Plasma Injection for The Management of Female Stress Urinary Incontinence

Abstract

Background: Stress urinary incontinence (SUI) is a prevalent condition among women that significantly affects quality of life. Aim: To evaluate the efficacy and feasibility of transvaginal ultrasound-guided periurethral platelet-rich plasma (PRP) injection in the treatment of female stress urinary incontinence. Methods: This prospective clinical study included 54 women diagnosed with SUI who were treated at Beni-Suef University Hospital between February 2023 and March 2024. All patients underwent transvaginal ultrasound-guided periurethral PRP injection, with a second injection administered after three months when indicated. Treatment outcomes were assessed using validated Arabic versions of the International Consultation on Incontinence Questionnaire–Short Form (ICIQ-UI-SF), ICIQ-LUTSqol, stress test, and pad weight test over a follow-up period of nine months. Results: After completion of treatment, 18.5% of patients were cured and 22.2% showed improvement, while 59.3% showed no response. Treatment efficacy was highest in patients with mild SUI (100% after the second injection), moderate in moderate SUI (36%), and lowest in severe SUI (31.3%). Significant improvement in quality of life scores was observed, particularly in mild and moderate cases. Younger age, lower parity, and cesarean delivery were associated with better outcomes. Conclusion: Transvaginal ultrasound-guided PRP injection is a safe and feasible minimally invasive treatment option for female stress urinary incontinence, with the greatest benefit observed in mild cases. Further randomized controlled trials are recommended to validate these findings and optimize patient selection